No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Diagnostics & Research
Founded in 2014 and headquartered in Richmond, Australia, Monash IVF Group Limited delivers specialized reproductive assistance and women's imaging services. Its operations span Australia and Malaysia, offering a broad spectrum of care. This includes diagnostic obstetric and gynecological ultrasound examinations, a range of fertility treatments, and advanced tertiary-level prenatal diagnostics. The company is also a key provider of in-vitro fertilization (IVF) services.
www.monashivfgroup.com.auNo one on the platform currently holds MVF.AX.
No tracked institution reports a position in MVF.AX as of their last filing.
No one on the platform has traded MVF.AX yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 3.3% | — | — | — | ||
| Rev. Growth % | -0.9% | 8.0% | ||||
| Profit Margin % | 2.8% | 5.8% | 9.7% | |||
| Free Cash Flow Margin % | 2.7% | 6.0% | 10.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $281M | +5.7% | $0.05 | $0.04–$0.05 | — | 5 |
| 2028 | $294M | +4.6% | $0.05 | $0.05–$0.06 | — | 5 |
| 2029 | $307M | +4.5% | $0.06 | $0.05–$0.07 | — | 5 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-30 | $0.02 | $0.01 | -33.9% |
| 2026-02-25 | $0.03 | $0.02 | -29.4% |
| 2025-08-21 | $0.03 | $0.03 | -1.6% |
| 2025-02-26 | $0.04 | $0.04 | +8.7% |
| 2024-08-21 | $0.04 | $0.04 | -2.3% |
| 2024-02-22 | $0.04 | $0.04 | -2.3% |
| 2023-08-21 | $0.03 | $0.03 | +4.6% |
| 2023-02-20 | $0.03 | $0.03 | -15.5% |
| +0.00% |
| $38M |
| — |
| DXB.AXDimerix Limited | $0.23 | -2.08% | $141M | — |
| IMR.AXImricor Medical Systems, Inc. | $1.84 | -0.27% | $592M | — |
Source: Financial Modeling Prep · peers by sector/industry